Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oregovomab and Bevacizumab, Paclitaxel, Carboplatin in BRCA-wild Type Platinum Sensitive Recurrent Ovarian Cancer
NCT04938583Phase 2Active, not recruiting
- Sponsor
- CanariaBio
- Start
- Mar 2021
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of oregovomab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by CanariaBio. Started Mar 2021; status: active, not recruiting.
02
Drugs
oregovomab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04938583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04938583.